Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LMAT Stock Forecast 2025-2026
$84.53
Current Price
$1.92B
Market Cap
Buy 6
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to LMAT Price Targets
+42.0%
To High Target of $120.00
+27.8%
To Median Target of $108.00
+6.5%
To Low Target of $90.00
LMAT Price Momentum
+1.9%
1 Week Change
-2.6%
1 Month Change
-16.4%
1 Year Change
-8.3%
Year-to-Date Change
-19.9%
From 52W High of $105.55
+18.4%
From 52W Low of $71.42
📊 TOP ANALYST CALLS
Did LMAT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if LeMaitre Vascular is one of their latest high-conviction picks.
Latest LMAT Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, LMAT has a bullish consensus with a median price target of $108.00 (ranging from $90.00 to $120.00). The overall analyst rating is Buy (7.8/10). Currently trading at $84.53, the median forecast implies a 27.8% upside. This outlook is supported by 6 Buy, 5 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LMAT Analyst Ratings
6
Buy
5
Hold
0
Sell
LMAT Price Target Range
Low
$90.00
Average
$108.00
High
$120.00
Current: $84.53
Latest LMAT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LMAT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 7, 2025 | Wells Fargo | Nathan Treybeck | Equal-Weight | Maintains | $93.00 |
| Nov 5, 2025 | Roth Capital | Kyle Bauser | Buy | Reinstates | $108.00 |
| Oct 15, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $95.00 |
| Sep 23, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $95.00 |
| Aug 6, 2025 | Cantor Fitzgerald | Ross Osborn | Neutral | Maintains | $95.00 |
| Aug 6, 2025 | Barrington Research | Michael Petusky | Outperform | Upgrade | $95.00 |
| Jul 22, 2025 | Barrington Research | Michael Petusky | Market Perform | Reiterates | $N/A |
| Feb 28, 2025 | Lake Street | Brooks O'Neil | Buy | Maintains | $110.00 |
| Feb 28, 2025 | Citizens Capital Markets | Daniel Stauder | Buy | Maintains | $110.00 |
| Feb 28, 2025 | Barrington Research | Michael Petusky | Market Perform | Downgrade | $N/A |
| Feb 13, 2025 | Wells Fargo | Nathan Treybeck | Equal-Weight | Initiates | $95.00 |
| Nov 1, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $93.00 |
| Nov 1, 2024 | Oppenheimer | Suraj Kalia | Outperform | Reiterates | $93.00 |
| Oct 15, 2024 | Cantor Fitzgerald | Ross Osborn | Neutral | Initiates | $96.00 |
| Sep 20, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $92.00 |
| Aug 20, 2024 | JMP Securities | Daniel Stauder | Market Outperform | Maintains | $100.00 |
| Aug 2, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $92.00 |
| May 31, 2024 | Roth MKM | Jason Wittes | Buy | Reinstates | $100.00 |
| May 3, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $79.00 |
| May 3, 2024 | JMP Securities | Daniel Stauder | Market Outperform | Maintains | $77.00 |
Lemaitre Vascular Inc. (LMAT) Competitors
The following stocks are similar to LeMaitre Vascular based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LMAT
LeMaitre Vascular
mkt cap
1.92B
Lemaitre Vascular Inc. (LMAT) Financial Data
Lemaitre Vascular Inc. has a market capitalization of $1.92B with a P/E ratio of 36.4x. The company generates $240.87M in trailing twelve-month revenue with a 22.1% profit margin.
Revenue growth is +11.4% quarter-over-quarter, while maintaining an operating margin of +33.3% and return on equity of +15.0%.
Valuation Metrics
Market Cap
$1.92B
Enterprise Value
$1.76B
P/E Ratio
36.4x
PEG Ratio
0.7x
Price/Sales
8.0x
Growth & Margins
Revenue Growth (YoY)
+11.4%
Gross Margin
+75.3%
Operating Margin
+33.3%
Net Margin
+22.1%
EPS Growth
+55.8%
Financial Health
Cash/Price Ratio
+17.9%
Current Ratio
13.6x
Debt/Equity
49.0x
ROE
+15.0%
ROA
+7.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lemaitre Vascular Inc. (LMAT) Business Model
About Lemaitre Vascular Inc.
What They Do
Develops innovative surgical solutions for vascular disease.
Business Model
Lemaitre Vascular Inc. generates revenue by designing, manufacturing, and selling a diverse array of medical devices, including grafts, stents, and biologic solutions tailored for vascular surgery and diagnostic procedures. The company targets healthcare professionals and institutions, providing essential tools that facilitate effective treatment for peripheral vascular conditions.
Additional Information
With a strong emphasis on research and development, Lemaitre Vascular is committed to advancing medical technology and improving patient outcomes. Its extensive product portfolio and focus on innovation position it well within the growing cardiovascular and peripheral vascular markets, which are critical for the healthcare industry.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
651
CEO
Mr. George W. LeMaitre
Country
United States
IPO Year
2006
Website
www.lemaitre.comLemaitre Vascular Inc. (LMAT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Zacks.com featured highlights include Life Time, Cardinal Health, LeMaitre Vascular and Flowserve
LTH, CAH, LMAT and FLS emerge as high-coverage-ratio standouts for investors seeking sturdier balance-sheet safety into 2026.
Dec 02, 2025
By Zacks Equity Research
Press Releases
4 Stocks With High Coverage Ratios Offer Safer Bets Going Into 2026
High coverage ratios and earnings growth make CAH, LTH, LMAT and FLS safer investment bets heading into 2026.
Dec 01, 2025
By Sumit Singh
Analyst Blog
Here is Why Growth Investors Should Buy LeMaitre (LMAT) Now
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Nov 27, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
CAH, LTH, LMAT, and FLS are identified as safer investment options due to their high coverage ratios and earnings growth, with favorable outlooks into 2026.
Why It Matters
High coverage ratios and earnings growth indicate financial stability and lower risk for CAH, LTH, LMAT, and FLS, making them attractive options for long-term investment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
LeMaitre (LMAT) shows above-average financial growth, positioning it well to potentially outperform the market.
Why It Matters
LeMaitre's above-average growth signals strong financial health, potentially leading to higher returns and increased investor confidence, making it an attractive investment opportunity.
Source: Zacks Investment Research
Market Sentiment:
Positive
New Strong Buy Stocks for November 14th
23 days ago
Quick Summary
Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, indicating a positive outlook for these investments.
Why It Matters
Stocks on the Zacks Rank #1 list indicate strong buy signals, suggesting potential for price appreciation and positive earnings momentum, attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will participate in three investor conferences, as announced on November 12, 2025.
Why It Matters
LeMaitre Vascular's participation in investor conferences signals potential growth and transparency, which may influence investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
LeMaitre (LMAT) is expected to outperform the market due to above-average growth in its financial performance.
Why It Matters
LeMaitre's above-average growth signals strong financial health, potentially leading to higher returns and increased investor confidence, making it an attractive investment opportunity.
Source: Zacks Investment Research
Market Sentiment:
Positive
Final Trade: LMAT, REGN, BA, TJX
25 days ago
Quick Summary
CNBC's Melissa Lee and the 'Fast Money' traders discussed the final trades of the day, offering insights into market movements and investment strategies.
Why It Matters
Final trades can signal market sentiment and emerging trends, offering insights into strategic investment decisions and potential stock movements for investors.
Source: CNBC Television
Market Sentiment:
Neutral
Frequently Asked Questions About LMAT Stock
What is Lemaitre Vascular Inc.'s (LMAT) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Lemaitre Vascular Inc. (LMAT) has a median price target of $108.00. The highest price target is $120.00 and the lowest is $90.00.
Is LMAT stock a good investment in 2026?
According to current analyst ratings, LMAT has 6 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $84.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LMAT stock?
Wall Street analysts predict LMAT stock could reach $108.00 in the next 12 months. This represents a 27.8% increase from the current price of $84.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lemaitre Vascular Inc.'s business model?
Lemaitre Vascular Inc. generates revenue by designing, manufacturing, and selling a diverse array of medical devices, including grafts, stents, and biologic solutions tailored for vascular surgery and diagnostic procedures. The company targets healthcare professionals and institutions, providing essential tools that facilitate effective treatment for peripheral vascular conditions.
What is the highest forecasted price for LMAT Lemaitre Vascular Inc.?
The highest price target for LMAT is $120.00 from at , which represents a 42.0% increase from the current price of $84.53.
What is the lowest forecasted price for LMAT Lemaitre Vascular Inc.?
The lowest price target for LMAT is $90.00 from at , which represents a 6.5% increase from the current price of $84.53.
What is the overall LMAT consensus from analysts for Lemaitre Vascular Inc.?
The overall analyst consensus for LMAT is bullish. Out of 15 Wall Street analysts, 6 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $108.00.
How accurate are LMAT stock price projections?
Stock price projections, including those for Lemaitre Vascular Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 5:43 PM UTC